Study to investigate the safety, tolerability and activity of AZD5069 when given as a single dose to healthy male and/or female subjects

Study identifier:D3550C00001

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZD5069 after Single Ascending Doses in Healthy Male and/or Female Subjects

Medical condition

Healthy

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD5069, Placebo

Sex

All

Actual Enrollment

203

Study type

Interventional

Age

18 Years - 65 Years

Date

Study Start Date: 01 Jul 2009

Primary Completion Date: 01 Dec 2009

Study Completion Date: 01 Dec 2009

Study design

Allocation: Randomized
Endpoint Classification: Pharmacokinetics/dynamics Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science

Verification:

Verified 01 Jun 2015 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Research Site

Nottingham, United Kingdom

Arms	Assigned Interventions
Experimental: Active AZD5069 oral solution	Drug: AZD5069 Single dose of oral solution.
Placebo Comparator: Placebo Placebo oral solution	Drug: Placebo Single dose of oral solution.

"There is no result for the study"

Documents available

CSR Synopsis
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Volunteer recruitment officer

01509 645950

Nottingham.volunteers@astrazeneca.com

Investigators

Principal Investigator

Andrew Sparrow

AstraZeneca Clinical Pharmacology Unit, Queens Medical Centre, Nottingham NG7 2UH